Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study
- 2 August 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), e253-e262
- https://doi.org/10.1016/j.clcc.2021.07.008
Abstract
No abstract availableFunding Information
- Bayer
This publication has 30 references indexed in Scilit:
- Evolving role of regorafenib for the treatment of advanced cancersCancer Treatment Reviews, 2020
- Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerCancers, 2020
- Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-AnalysisClinical Colorectal Cancer, 2020
- Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patientsFuture Oncology, 2020
- Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyThe Oncologist, 2018
- Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?Acta Endocrinologica, 2017
- The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximabBritish Journal of Cancer, 2017
- Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programBMC Cancer, 2016
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2015
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013